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1. Introduction 
The quinolones are a family of synthetic broad-spectrum 
antibacterial drugs [1-3].  The first generation of quinolones began 
with the introduction of nalidixic acid for treatment of urinary tract 
infections in humans [4]. Nalidixic acid was discovered in a distillate 
during an attempt at chloroquine synthesis [5]. Quinolones exert 
their antibacterial effect by preventing bacterial DNA from 
unwinding and duplicating [6]. The majority of quinolones in clinical 
use belong to the subset fluoroquinolones (FQLs), which have a 
fluorine atom attached to the central ring system, typically at the 6-
position or C-7 position. 
1.1 History 
Nalidixic acid is considered to be the predecessor of all 
quinolone family, including the second, third and fourth generations 
commonly known as fluoroquinolones (FQLs). Though it is generally 
accepted nalidixic acid is to be considered the first quinolone drug, 
this has been disputed over the years by a few researchers who 
believe chloroquine, from which nalidixic acid is derived, is to be 
considered the first quinolone drug, rather than nalidixic acid. The 
1,8-naphthyridine-type agent nalidixic acid, is the predecessor of 
quinolone antibacterials, the matter has been contested by a few 
researchers who promote chloroquine, from which nalidixic acid was 
derived. The various quinolones are nalidixic acid, extensive 
quinolone family, which includes second, third, and fourth generation 
quinolones, and further agents under development. This first, 
nalidixic acid generation included other such "quinolone" drugs as 
oxolinic acid (a true 4-quinolone), pipemidic acid (a 
pyridopyrimidine), and cinoxacin (a cinnoline), all introduced in the 
1970s. Each proved to be only marginal improvements over nalidixic 
acid [7]. Since the introduction of nalidixic acid in 1962, more than 
10,000 quinolone analogs have been synthesized; and as is standard 
in modern medicinal chemistry, a handful have found their way into 
wide clinical practice [8,9]. 
 
2. Quinolones as antibacterials 
Quinolones are a family of synthetic broad-spectrum 
agents used as anti-bacterial agents [3]. The first generation of the 
quinolones began following introduction of the related, but 
structurally distinct naphthyridine-family nalidixic acid in 1962 for 
treatment of urinary tract infections in humans [4]. Nalidixic acid was 
discovered by George Lesher and coworkers in a chemical distillate 
during an attempt at synthesis of the chloroquinoline antimalarial 
agent, chloroquine [5]. Naphthyridone and quinolone classes of 
antibiotics prevent bacterial DNA replication by inhibition of DNA 
unwinding events, and can be both bacteriostatic and bacteriocidal 
[6]. The majority of quinolones in clinical use belong to the second 
generation class of "fluoroquinolones", which have a true quinoline 
framework, maintain the C-3 carboxylic acid group, and add a 
fluorine atom to the all-carbon containing ring, typically at the C-6 or 
C-7 positions. 
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Figure 1a: Structure of some first generation quinolone 
derivatives 
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Figure 1b: Structure of some second generation quinolone 
derivatives 
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Figure 1c: Structure of some third generation quinolone 
derivatives 
Abstract 
The quinolones are a class of bicyclic molecules, organic chemical structures 
that are related to the heteroaromatic coal tar isolate quinoline. Quinolone antibacterials 
are widely used. Specific quinoline molecules substituted with an hydroxyl functional 
group at carbons 2 and 4 are most often observed in isomeric forms termed 2- and 4-
quinolones, respectively. The relative importance of 4-quinolones has increased with the 
discovery that such structures that also bear a carboxylic acid (-COOH) and other 
functional groups at particular sites on the ring have very potent bacteriocidal activities, 
inhibiting of a broad spectrum of Gram negative and Gram positive DNA gyrase and 
topoisomerase enzymes. Hence, they are very useful in antibacterial therapy.  
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Figure 1d: Structure of some fourth generation quinolone 
derivatives 
Figure 1: Structure of first (1a), second (1b), third (1c) and 
fourth (1d) generation quinolone derivatives. 
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Figure 2: Structure of some newer quinolone derivatives 
 
2.1 Pharmacology 
The basic pharmacophore, or active structure, of the 
fluoroquinolone (FQL) class is based upon the quinoline ring system 
[10]. The addition of the fluorine atom at C6 distinguishes the 
successive-generation FQLs from the first-generation quinolones. The 
addition of the C6 fluorine atom has since been demonstrated to not 
be required for the antibacterial activity of this class [11]. Various 
substitutions made to the quinoline ring resulted in the development 
of numerous FQL drugs available today. Each substitution is 
associated with a number of specific adverse reactions, as well as 
increased activity against bacterial infections, whereas the quinoline 
ring, in and of itself, has been associated with severe and even fatal 
adverse reactions [12]. 
2.2 Generations 
Researchers divide the quinolones into generations based 
on their antibacterial spectrum [13]. The earlier-generation agents 
are, in general, more narrow-spectrum than the later ones, but no 
standard is employed to determine which drug belongs to which 
generation. The only universal standard applied is the grouping of 
the non-fluorinated drugs found within this class (quinolones) within 
the 'first-generation' heading. The first generation is rarely used 
today. Nalidixic acid was list as a carcinogen on 15 May 1998 [14]. A 
number of the second-, third-, and fourth-generation drugs have been 
removed from clinical practice due to severe toxicity issues or 
discontinued by their manufacturers. The first generation is rarely 
used today. The drugs most frequently prescribed today consist of 
moxifloxacin, ciprofloxacin, levofloxacin and, to some extent, their 
generic equivalents. 
First-generation: Various first generation quinolones such as 
cinoxacin, flumequine (veterinary use), nalidixic acid, oxolinic acid, 
piromidic acid, pipemidic acid, and rosoxacin [15] 
Second-generation: The second-generation class is sometimes 
subdivided into Class 1 and Class 2 [15,16]. Examples are 
ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, 
norfloxacin, ofloxacin, pefloxacin and rufloxacin, 
Third-generation: Unlike the first- and second-generations, the 
third-generation is active against streptococci [15,16]. Examples are 
balofloxacin, Grepafloxacin, levofloxacin, pazufloxacin, sparfloxacin, 
temafloxacin, and tosufloxacin.  
Fourth-generation: Fourth-generation fluoroquinolones act at DNA 
gyrase and topoisomerase IV. This dual action slows development of 
resistance (15-16). This dual action slows development of resistance. 
Examples are clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin, 
sitafloxacin, trovafloxacin and prulifloxacin. 
In development: delafloxacin (an anionic fluoroquinoline in clinical 
trials), JNJ-Q2 (completed Phase II for MRSA), nemonoxacin.  
2.3 Medical uses 
Fluoroquinolones (FQLs) are broad-spectrum antibiotics 
(effective against both gram-negative and gram-positive bacteria) 
that play an important role in treatment of bacterial infections 
(especially hospital-acquired and resistance strains to older 
antibacterial). The use of broad-spectrum antibiotics encourage the 
spread of multidrug-resistant (MDR) strains and recommend 
minimizing the use of FQLs and other broad-spectrum antibiotics in 
less severe infections and in those in which risk factors for MDR are 
not present. FQLs are featured prominently for the treatment of 
hospital-acquired pneumonia [17]. The FQLs not be used as a first-
line agent for community-acquired pneumonia [18] instead 
recommending macrolide or doxycycline as first-line agents. The 
Drug-Resistant Streptococcus pneumoniae Working Group 
recommends FQLs be used for the ambulatory treatment of 
community-acquired pneumonia only after other antibiotic classes 
have been tried and failed, or in those with demonstrated drug-
resistant S. neumoniae [19]. The FQLs are often used for 
genitourinary infections, and are widely used in the treatment of 
hospital-acquired infections associated with urinary catheters. In 
community-acquired infections, they are recommended only when 
risk factors for MDR are present or after other antibiotic regimens 
have failed. However, for serious acute cases of pyelonephritis or 
bacterial prostatitis where the patient may need to be hospitalised, 
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FQLs are recommended as first-line therapy [20]. Due to sickle-cell 
disease patients' being at increased risk for developing osteomyelitis 
from the Salmonella genus, FQLs are the "drugs of choice" due to 
their ability to enter bone tissue without chelating it, as tetracyclines 
are known to do. 
Veterinary use: The quinolones have been widely used in 
agriculture, and several agents have veterinary, but not human, 
applications. For veterinary uses: danofloxacin, difloxacin, 
enrofloxacin, ibafloxacin, marbofloxacin, orbifloxacin, sarafloxacin. 
However, the agricultural use of FQLs has been restricted since 1997, 
due to concerns over the development of antibiotic resistance [ 
2.4 Adverse effects of fluoroquinolones:  
In general, fluoroquinolones (FQLs) are well tolerated, 
with most side-effects being mild to moderate [21]. On occasion, 
serious adverse effects occur [22]. Common side-effects include 
gastrointestinal effects such as nausea, vomiting, and diarrhea, as 
well as headache and insomnia. The overall rates of adverse events 
are roughly similar to seen in patients treated with other antibiotics 
[23-25]. Patients treated with FQLs experienced adverse events 
severe enough than those treated with cephalosporins or macrolides, 
but less frequently than those treated with penicillins, clindamycin, 
sulfonamides, or vancomycin [26]. A variety of relatively rare but 
serious adverse effects those are associated with all members of the 
FQL antibacterial class. Among these, tendon problems and 
exacerbation of the symptoms of the neurological disorder 
myasthenia gravis is the subject of warnings. The most severe form of 
tendonopathy associated with FQL administration is tendon rupture, 
which involves the Achilles tendon. Younger people experience good 
recovery, but permanent disability is possible, and is more likely in 
older patients [27]. The frequency of FQL-associated Achilles tendon 
rupture in patients treated with ciprofloxacin or levofloxacin is has 
been estimated at 17 per 100,000 treatments [21,28]. Risk is 
substantially elevated in the elderly and in those with recent 
exposure to corticosteroid therapy. Simultaneous use of 
corticosteroids is present in almost one-third of quinolone-associated 
tendon rupture [29]. Tendon damage may manifest during, as well as 
up to a year after FQL therapy has been completed [30]. FQs prolong 
the QT interval by blocking voltage-gated potassium channels [31]. 
Prolongation of the QT interval can lead to torsades de pointes, a life-
threatening arrhythmia, but in practice this appears relatively 
uncommon in part because the most widely prescribed FQLs 
(ciprofloxacin and levofloxacin) only minimally prolong the QT 
interval [32]. Clostridium difficile-associated diarrhea may occur in 
connection with the use of any antibacterial drug, especially with 
broad spectrum drugs like clindamycin, cephalosporins, and FQLs. 
The FQLs associated risk is simlar to [33] or less [34] than that 
associated with broad spectrum cephalosporins. The FQL 
administration may be associated with the acquisition and outgrowth 
of a particularly virulent Clostridium strain [35]. The neurotoxicity 
occurs in approximately 1% to 4.4% of patients taking FQs, with 
serious adverse effects occurring less than 0.5%.(24) The most 
important of these may be peripheral neuropathy, which can be 
permanent. Other nervous system effects include insomnia, 
restlessness, and rarely, seizure, convulsions, and psychosis [36]. 
Other rare and serious adverse events have been observed with 
varying degrees of evidence for causation [37-40]. Events that may 
occur in acute overdose are rare, and include renal failure and 
seizure [41]. Susceptible groups of patients, such as children and the 
elderly, are at greater risk of adverse reactions during therapeutic 
use [42]. 
Fluoroquinolones disadvantages or side effects 
 Tendonitis or tendon rupture 
 Multiple drug interactions 
 Not used in children 
 Newer quinolones produce additional toxicities to the heart that 
were not found with the older agents 
 Gastrointestinal effects 
 CNS effects: Headache, dizziness, and drowsiness have been 
reported with all fluoroquinolones. 
 Phototoxicity: The degree of phototoxic potential of 
fluoroquinolones is as follows: 
lomefloxacin>sparfloxacin>ciprofloxacin>norfloxacin=ofloxacin=le
vofloxacin=gatiflox-cin = moxifloxacin. 
 Musculoskeletal effects. 
 Hepatoxicity 
 Cardiovascular effects 
 Hypoglycemia/Hyperglycemia 
 Hypersensitivity 
Fluoroquinolone advantages: 
 Ease of administration 
 Daily or twice daily dosing 
 Excellent oral absorption 
 Excellent tissue penetration 
 Prolonged half-lives 
 Significant entry into phagocytic cells 
 Efficacy  
 Overall safety 
2.5 Contraindications 
Quinolones are contraindicated if a patient has epilepsy, 
QT prolongation, pre-existing CNS lesions, or CNS inflammation, or 
the patient has suffered a stroke [22]. The safety concerns of FQL use 
during pregnancy and, as a result, are contraindicated except for 
when no other safe alternative antibiotic exists [43]. However, the 
outcome of pregnancies involving quinolone use in the first trimester 
found no increased risk of malformations [44]. They are also 
contraindicated in children due to the risks of damage to the 
musculoskeletal system [45]. Their use in children is not absolutely 
contraindicated, however. For certain severe infections where other 
antibiotics are not an option, their use can be justified [46]. 
Quinolones should also not be given to people with a known 
hypersensitivity to the drug [47]. Quinolone antibiotics should not be 
administered to patients who are dependent on benzodiazepines, 
since they compete directly with benzodiazepines at the GABA-A 
receptor, acting as a competitive antagonist and thus possibly 
precipitating a severe acute and potentially fatal withdrawal effect 
[48-51]. 
2.6 Mechanism of action 
Quinolones and fluoroquinolones (FQLs) are 
chemotherapeutic bactericidal drugs, eradicating bacteria by 
interfering with DNA replication. Quinolones inhibit the bacterial 
DNA gyrase or the topoisomerase II ligase, thereby inhibiting DNA 
replication and transcription. Recent evidence has shown 
topoisomerase II is also a target for a variety of quinolone-based 
drugs. Thus far, most of the compounds that show high activity 
against the eukaryotic type II enzyme contain aromatic substituents 
at their C-7 positions [52,53]. Quinolones can enter cells easily and, 
therefore, are often used to treat intracellular pathogens such as 
Legionella pneumophila and Mycoplasma pneumoniae. For many 
Gram-negative bacteria, DNA gyrase is the target, whereas 
topoisomerase IV is the target for many Gram-positive bacteria. It is 
believed eukaryotic cells do not contain DNA gyrase or 
topoisomerase IV. However, there is debate concerning whether the 
quinolones still have such an adverse effect on the DNA of healthy 
cells. The FQLs inhibit the topoisomerase II ligase domain, leaving the 
two nuclease domains intact. This modification, coupled with the 
constant action of the topoisomerase II in the bacterial cell, leads to 
DNA fragmentation via the nucleasic activity of the intact enzyme 
domains. Some compounds in this class have been shown to inhibit 
the synthesis of mitochondrial DNA [54-56]. 
Mechanism of toxicity: The mechanisms of the toxicity of FQLs has 
been attributed to their interactions with different receptor 
complexes, such as blockade of the GABAa receptor complex within 
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the central nervous system, leading to excitotoxic type effects [22] 
and oxidative stress [57]. 
Interactions: Theophylline, nonsteroidal anti-inflammatory drugs 
and corticosteroids enhance the toxicity of FQLs [58.59]. Products 
containing multivalent cations, such as aluminium- or magnesium-
containing antacids and products containing calcium, iron, or zinc, 
invariably result in marked reduction of oral absorption of FQLs [60]. 
Taking colloidal silver along with several versions of quinolones 
might decrease how much antibiotic the body absorbs [61]. Other 
drugs that interact with FQLs include antacids, sucralfate, 
probenecid, cimetidine, warfarin, antiviral agents, phenytoin, 
cyclosporine, rifampin, pyrazinamide, and cycloserine [62]. Many 
FQLs, especially ciprofloxacin, inhibit the cytochrome P450 isoform 
CYP1A2. This inhibition causes an increased level of drugs that are 
metabolized by this enzyme. This includes antidepressants such as 
amitriptyline and imipramine, clozapine (an atypical antipsychotic), 
caffeine, olanzapine (antipsychotic), ropivacaine (local anaesthetic), 
theophylline, and zolmitriptan (serotonin receptor agonist).  
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Structure-Activity Relationship:  
Position 1: 
 Earlier study indicated that substitution at N-1 position is 
important for Anti-bacterial activity. 
 QSAR analysis of a set of N-1 allyl and alkyl derivatives suggested 
and optimum STERIMOL length of 0.42 nm, corresponding 
approximately to an ethyl group. 
 STERIMOL is a program that calculates a set of five parameters 
characterizing size and shape of a substituent. 
 STERIMOL length is defined as length of substituent along the axis 
of bond between the substituent and the parent molecule. 
 Subsequently, the discovery of potent quinolones with N-1 phenyl 
and N-1 cyclopropyl substitutions indicated that with respect to an 
N-1 substituent, in addition to steric bulk , there are other factors 
such as electronic- π donation and ideal spatial effects that also 
have a great influence on their biological activities . 
 Introduction of a t-butyl group at N-1 produced quinolones with 
enhanced activity against gram positive bacteria with minor 
reduction of activity against gram negative bacteria. 
 In general , cyclopropyl group appears to be optimum for activity. 
e.g Ciprofloxacin. 
Position-3: 
 Position 3 and 4, having a link between the carboxylic acid group 
and the keto group are generally considered necessary for binding 
of quinolones to DNA gyrase. 
 Classical studies have produced no active quinolone with a 
significant modification of C-3 carboxylic acid group, with 
exception of groups which are converted in vivo to carboxylic acid 
group. 
Position-4:  
 Position-4 has not been extensively explored and replacement of 
4- keto group with other groups has generally produced inactive 
or weakly active compounds. 
Position-5: 
 Compounds with small substituents such as nitro, amino, halo, 
alkyl groups have been synthesized. Among them, C-5 amino group 
enhances absorption and / or tissue distribution . e.g Sparfloxacin. 
 The incidence of photo toxicity of Sparfloxacin is the lowest of the 
fluoroquinolones , because of the presence of the 5-amino group , 
which counteracts the effect of the 8- fluoro substituent . 
Position-6: 
 Of various C-6 substituents, H, Cl, Br, F, CH3, S- CH3, CO CH3, CN, 
NO2 etc the addition of a fluorine atom resulted in a dramatic 
increase in anti-bacterial potency. 
 Fluoro group at C-6 seems to improve both the DNA gyrase 
complex binding (2 to 17 folds) and cell penetration (1 to 70 folds) 
of the corresponding derivatives with no substitution at C-6. 
Position-7: 
 C-7 piperazinyl group in addition to C-6 fluorine substituent has 
anti-bacterial potency for superior to that of earlier classical 
quinolones against both gram-positive and gram-negative bacteria. 
 In general, quinolones with small or linear C-7 substituents (H, Cl, 
CH3, NH2-CH2-CH2- NH2, NH- CH3, NH-NH2) 
 Possess moderate to weak anti-bacterial activities. 
 Various substitutions tried at C-7 position are- 
 substituted piperazinyl 
 substituted pyrrolidinyl 
 substituted morpholinyl 
 In general, the substitution of methyl at C-4 position of the 
piperazinyl group enhances gram-positive anti-bacterial activity 
with slight decrease in gram-negative activity. 
Position -8: 
 C-8 fluoro or chloro derivatives are more active in-vivo, owing to 
better oral absorption. 
 Oxygen substituent at C-8 position, where substituent is part of 
ring system has been shown to have better in vivo efficacy . 
 C-8 methoxy or ethoxy group appears to increase the spectrum of 
activity. 
 C-8 methoxy ( e.g Gatifloxacin ) has been shown to contribute 
significant activity against anaerobes. 
Antibiotic misuse and bacterial resistances: Resistance to 
quinolones can evolve rapidly, even during a course of treatment. 
Numerous pathogens, including Staphylococcus aureus, enterococci, 
and Streptococcus pyogenes now exhibit resistance worldwide. 
Widespread veterinary usage of quinolones, in particular in Europe, 
has been implicated [63]. Fluoroquinolones (FQLs) have been 
recommended to be reserved for the use in patients that are seriously 
ill and may soon require immediate hospitalization [64]. Though 
considered to be very important and necessary drugs required to 
treat severe and life-threatening bacterial infections, the associated 
antibiotic misuse remains unchecked, which has contributed to the 
problem of bacterial resistance. The overuse of antibiotics such as 
happens with children suffering from otitis media (ear infections) has 
given rise to a breed of super-bacteria that are resistant to antibiotics 
entirely [65]. For example, the use of the FQLs had increased 
threefold in an emergency room environment in the United States 
between 1995 and 2002, while the use of safer alternatives, such as 
macrolides, declined significantly [19]. FQLs had become the most 
commonly prescribed class of antibiotics to adults in 2002. Nearly 
half (42%) of these prescriptions were for conditions, such as acute 
bronchitis, otitis media, and acute upper respiratory tract infection 
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[66]. In addition, they are commonly prescribed for medical 
conditions, such as acute respiratory illness, that are usually caused 
by viral infections [67,68]. Three mechanisms of resistance are 
known [69]. Some types of efflux pumps can act to decrease 
intracellular quinolone concentration [70]. In Gram-negative 
bacteria, plasmid-mediated resistance genes produce proteins that 
can bind to DNA gyrase, protecting it from the action of quinolones. 
Finally, mutations at key sites in DNA gyrase or topoisomerase IV can 
decrease their binding affinity to quinolones, decreasing the drugs' 
effectiveness. All FQLs antibacterial drugs describe the serious side 
effect of peripheral neuropathy. This serious nerve damage 
potentially caused by FQLs may occur soon after these drugs are 
taken and may be permanent. Only those taken by mouth or injection 
were covered by the alert, while those used topically on the eyes and 
ears were not. Several advocacy groups have petitioned the FDA to 
increase the prominence of adverse effect warnings on the labels of 
FQL antibacterials, and to withdraw others from the market [71-74]. 
Fluoroquinolone (FQL) antibiotics increased risk of developing 
tendonitis and tendon rupture in patients of all ages taking FQLs for 
systemic use. This risk is increased in the individuals who are over 60 
years of age, taking corticosteroid drugs, and have kidney, heart, or 
lung transplants. FQLs, due to their neuromuscular blocking activity, 
may exacerbate muscle weakness in persons with myasthenia gravis. 
Serious adverse events, including deaths and requirement for 
ventilatory support, have been reported in this group of patients. 
Avoidance of FQLs in patients with known history of myasthenia 
gravis is advised [75-77]. 
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